When assessing the resultant E7-specific immune response generated by the various treatment strategies, significantly stronger systemic and tumor-infiltrating E7-specific CD8+ T cell responses were detected in TC-1 tumor-bearing mice treated with cisplatin, E7 long peptide, and AnxA5, as compared to mice in other treatment groups (Fig. 1d, e). The gene discussed is CD8A; the disease is neoplasm.